Probius receives grant to advance revolutionary tuberculosis diagnostic platform for resource-limited settings
Summary
Probius received a grant to advance its AI-powered QES point-of-care tuberculosis screening platform, which eliminates sample preparation and delivers results in about 30 minutes. The funding will support preclinical validation and aims to push per-test costs well below current molecular diagnostics by enabling reagent- and sample-prep-free, matrix-agnostic testing. Probius will work with the FEND-TB consortium for clinical validation in high-burden countries and plans to miniaturize the technology into handheld, battery-operated devices with FDA clearance and WHO prequalification pathways. The platform combines quantum electrochemical sensors with AI to capture comprehensive molecular signatures, enabling disease-agnostic multiplexing and potential expansion beyond TB.